1. Discover recent advances in the literature on ABO-incompatible (ABOi) transplantation, including alternative strategies, novel antibody testing methods, complications, and outcomes.

2. Evaluate the effectiveness and suitability of current desensitization therapies in the context of ABOi transplantation.

3. Distinguish emerging therapies in the pipeline for their potential application in ABOi transplantation.

4. Assess clinical scenarios involving patients with ABOi living donors to determine transplant eligibility and challenges.

5. Develop a personalized desensitization plan for a patient undergoing evaluation for ABOi transplantation.

1. Analyze the literature using novel immunosuppressive agents as monotherapy or combination therapy with respect to their recent use in highly sensitized transplant candidates.

2. Develop a desensitization plan for a highly sensitized transplant candidate according to the recent literature.

3. Develop a plan for detecting and potentially treating early antibody-mediated rejection in a transplant recipient undergoing desensitization.

1. Analyze the underlying pathophysiology, clinical presentation, and identifiable risk factors contributing to the development and progression of cardiac allograft vasculopathy (CAV) and chronic lung allograft dysfunction (CLAD).

2. Assess the usefulness of different diagnostic modalities for detection of CAV and CLAD and develop a monitoring plan.

3. Evaluate the benefits and gaps of the pharmacotherapy agents used to prevent and manage CAV and CLAD.

4. Construct a pharmacotherapy plan for patients with CAV and CLAD.

1. Evaluate and interpret respiratory virus diagnostic testing.

2. Assess indications for respiratory viral prophylaxis in solid organ transplant recipients (SOTRs).

3. Devise and justify the use of therapies for the treatment of respiratory viral infections (RVIs).

4. Compose individualized immunosuppressive regimens in the context of concomitant RVI.

5. Develop monitoring plans to identify and manage complications of RVIs.

1. Justify the clinical rationale for using hepatitis C virus (HCV)-, hepatitis B virus (HBV)-, and HIV-positive donor organs to expand the solid organ transplant pool.

2. Develop evidence-based strategies to manage transplantation of HCV-positive donor organs including appropriate candidate selection, use of direct-acting antivirals, and posttransplant monitoring, to optimize recipient outcomes and mitigate risks of viral transmission and graft complications.

3. Formulate management strategies for transplantation of HBV-positive donor organs, incorporating pretransplant vaccination, antiviral prophylaxis, and posttransplant surveillance, to reduce transmission risk and optimize long-term recipient outcomes.

4. Design management approaches for HIV-positive donor to HIV-positive recipient transplantation, emphasizing antiretroviral regimen optimization, drug-drug interaction monitoring, and infection surveillance, to ensure graft function and recipient safety.

5. Discover the ethical, legal, and policy considerations surrounding the use of HCV-, HBV-, and HIV-positive donor organs.

1. Distinguish the potential risks associated with pretransplant opioid use on posttransplant outcomes, including graft survival and patient mortality.

2. Assess the differences in mechanisms of multimodal pain agents and how they differ from opioids.

3. Demonstrate how to apply multimodal analgesic strategies (eg, transversus abdominis plane [TAP] block, acetaminophen, gabapentin) in creating a pain management plan for living donation.

4. Assess the efficacy and safety outcomes of opioid minimization protocols across different organ transplant types.

5. Develop an institutional policy framework for opioid stewardship in solid organ transplantation, integrating patient education, preoperative risk assessment, and discharge prescribing guidelines.

1. Analyze the evolving role of the transplant pharmacist to account for how technology integration enhances medication management, care coordination, and patient education across the transplant continuum.

2. Evaluate how telepharmacy, electronic health record optimization, clinical decision support, and remote monitoring technologies can be applied to optimize safety, efficiency, and continuity of transplant care.

3. Assess the effectiveness of digital education platforms, mobile applications, and gamified learning tools in improving transplant recipient comprehension, engagement, and medication adherence.

4. Design and devise technology-driven strategies to integrate into the transplant care workflow that enhance interdisciplinary collaboration, optimize pharmacotherapy management, and measure patient-centered outcomes.

5. Analyze and justify approaches to overcome barriers to technology adoption—such as data privacy, patient access, and provider resistance—while maintaining ethical and regulatory compliance.

1. Assess changes to recommended immunizations for pediatric solid organ transplant (SOT) recipients and candidates.

2. Evaluate the use of newer antimicrobial agents, vaccines, and antibodies in pediatric SOT recipients and candidates at risk of infectious complications.

3. Analyze the current recommendations on the management of cytomegalovirus (CMV) in pediatric SOT recipients.

4. Design treatment plans for pediatric SOT recipients with BK virus in accordance with the current guideline recommendations.

1. Assess the benefits and risks of available contraceptive methods for a solid organ transplant recipient.

2. Construct a reproductive-health counseling plan for a sexually active solid organ transplant recipient.

3. Evaluate the maternal, graft, and fetal outcomes of pregnancy after solid organ transplant.

4. Design a safe immunosuppression regimen and monitoring plan for a solid organ transplant recipient during pregnancy and breastfeeding.